RVRCOTCPharmaceutical PreparationsFiscal year ends December 31
Revium Rx.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.43+0.00 (0.00%)
Close on Oct 16, 2026
- Market cap
- $86.84M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
6 of Revium Rx.'s most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 13, 2026 | SEC EDGAR |
| Current report | 8-K | Jun 16, 2026 | Jun 22, 2026 | SEC EDGAR |
| Current report | 8-K | May 27, 2026 | Jun 1, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 14, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 14, 2026 | Apr 20, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 31, 2026 | SEC EDGAR |